PCDHA2 Antibody

What is PCDHA2 and what is its role in neuronal development?

PCDHA2 (Protocadherin Alpha 2) is a single-pass type I membrane protein containing 6 cadherin domains that belongs to the protocadherin family, the largest subgroup within the cadherin superfamily . Protocadherins are predominantly expressed in the nervous system and are integrally involved in the regulation of neuronal recognition and connectivity . The protocadherin subfamily is divided into three groups: the clustered protocadherins (comprising α-, β- and γ-protocadherins), δ-protocadherins, and other solitary forms . As part of the alpha cluster, PCDHA2 likely contributes to the remarkable diversity of cell surface recognition molecules that enable precise neuronal circuit formation during development.

The molecular structure of PCDHA2 is characterized by:

• Calculated molecular weight of 102 kDa

• UniProt Primary Accession Number: Q9Y5H9

• Gene ID (NCBI): 56146

• Contains extracellular cadherin domains involved in cell-cell recognition

Recent developmental studies have shown differential expression patterns of protocadherin clusters during embryonic and adult stages, suggesting temporally regulated functions that extend beyond simple cell adhesion to include roles in synaptic specificity and neural circuit formation.

How is PCDHA2 expression regulated during development, and how does it differ from other protocadherin family members?

PCDHA2 expression demonstrates specific developmental regulation patterns that distinguish it from other protocadherin family members. Research analyzing protocadherin isoform expression across diverse somatic cell types has revealed significant developmental stage-specific regulation . While some alpha cluster protocadherins such as PCDHA4 show significant up-regulation in embryonic cells compared to adult counterparts (with a mean fold-change of 36.1 in embryonic versus adult expression), PCDHA2 shows a distinct expression profile .

The regulation of clustered protocadherin loci appears highly coordinated:

• Alpha cluster members (including PCDHA2) and beta cluster members like PCDHB2 are often up-regulated in embryonic cells (particularly progenitor cells and embryonic progenitors) compared to adult non-embryonic cells

• Gamma cluster members show more heterogeneous expression patterns, with some up-regulated in embryonic cells (PCDHGB4, PCDHGB6) and others in adult cells (PCDHGB5, PCDHGA12)

• Cancer cell lines often demonstrate a shift toward an embryonic pattern of clustered protocadherin locus gene expression

This differential regulation suggests that PCDHA2 participates in both developmental processes and potentially maintains specific functions in mature tissues, albeit at different expression levels. Understanding these expression patterns is crucial for interpreting experimental results when studying PCDHA2 in different cellular contexts or disease models.

What criteria should researchers consider when selecting a PCDHA2 antibody for specific experimental applications?

Selecting the appropriate PCDHA2 antibody requires careful consideration of multiple experimental parameters to ensure reliable and reproducible results. Based on current research practices, the following criteria are essential:

For advanced applications, researchers should also consider:

• Previously published data using the same antibody

• Verification of specificity through knockout/knockdown controls

• Batch-to-batch consistency information from manufacturers

• Performance in tissue-specific contexts relevant to your research

Experimental validation should always include appropriate positive controls such as brain tissue for PCDHA2, as this protein is predominantly expressed in the nervous system . For Western blot applications, a dilution of 1:500-1:1000 is typically recommended, though optimization for specific experimental conditions is advisable .

How can researchers validate PCDHA2 antibody specificity to avoid polyreactivity issues commonly found in neuronal research?

Antibody polyreactivity—the binding of an antibody to multiple unrelated antigens—poses a significant challenge in neuroscience research. For PCDHA2 antibodies, implementing a comprehensive validation strategy is essential to ensure experimental reliability:

• Multiple Technique Validation: Confirm PCDHA2 detection using orthogonal methods such as:

  • Western blot to verify the molecular weight (expected at 102 kDa, with some reports of an 80 kDa band)

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • RNA knockdown/knockout validation to demonstrate specificity

• Negative Controls: Include samples known to lack PCDHA2 expression or use:

  • Isotype control antibodies to establish baseline non-specific binding

  • Pre-absorption with immunizing peptide to confirm epitope-specific binding

• Cross-Reactivity Assessment: Recent studies on antibody polyreactivity have developed assays testing reactivity against a panel of biochemically diverse targets . For PCDHA2 antibodies, testing against:

  • DNA, insulin, lipopolysaccharide (LPS), flagellin, albumin, cardiolipin, and keyhole limpet hemocyanin (KLH) can identify potential polyreactivity issues

• Sequence Analysis Verification: Biochemical patterns of antibody polyreactivity can be analyzed through sequence-based approaches that:

  • Minimize structural assumptions while maintaining positional context of amino acid sequences

  • Provide unbiased analysis of existing data

• Application-Specific Validation: For PCDHA2 research particularly:

  • Verify detection in positive control tissues (brain tissue from the species of interest)

  • Test across multiple cell types with documented PCDHA2 expression patterns

  • Include both embryonic and adult samples if studying developmental processes

Implementing these validation steps helps distinguish true PCDHA2 detection from non-specific binding, particularly important given the sequence similarity between protocadherin family members and the potential for cross-reactivity with other alpha-cluster protocadherins.

What are the optimal experimental conditions for detecting PCDHA2 in different tissue types and developmental stages?

Detecting PCDHA2 across different tissue types and developmental stages requires optimized experimental conditions that account for expression level variations and tissue-specific factors:

Western Blot Protocol Optimization for PCDHA2 Detection:

For developmental stage analysis, consider these additional factors:

• Embryonic tissues often show higher expression of PCDHA2 compared to adult tissues

• Cancer cell lines may exhibit an embryonic-like expression pattern

• Comparison between embryonic progenitors and adult non-embryonic cells requires careful normalization

Immunohistochemistry/Immunofluorescence Considerations:

• Fixation: 4% paraformaldehyde is typically suitable

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody incubation: Overnight at 4°C

• Counter-staining with neuronal markers to establish cellular context

When comparing expression across developmental stages, it is essential to maintain consistent experimental conditions and include appropriate loading controls for quantitative analyses.

How should researchers design experiments to study PCDHA2 function in neuronal connectivity and recognition?

Designing robust experiments to investigate PCDHA2 function in neuronal connectivity requires integrating molecular techniques with functional assays:

1. Expression Manipulation Approaches:

• CRISPR/Cas9-mediated knockout/knockin of PCDHA2

• shRNA or siRNA knockdown for transient suppression

• Overexpression studies using full-length PCDHA2 or dominant-negative constructs

• Conditional expression systems for temporal control

2. Co-culture Assays for Cell Recognition:

• Mixed culture of neurons expressing different fluorescent markers

• Time-lapse imaging to track cell sorting and preferential interactions

• Quantification of homophilic versus heterophilic cell clustering

3. Synaptogenesis and Circuit Formation Analysis:

• High-resolution imaging of synaptic markers in PCDHA2-manipulated neurons

• Electrophysiological recording to assess functional connectivity

• Trans-synaptic tracing to map circuit alterations

4. Molecular Interaction Studies:

• Co-immunoprecipitation to identify PCDHA2 binding partners

• Proximity ligation assays to confirm interactions in situ

• FRET/BRET approaches to measure dynamic interactions

5. Developmental Timeline Analysis:

• Comparison of PCDHA2 function across embryonic and postnatal stages

• Correlation with critical periods of neural circuit formation

• Analysis of compensatory mechanisms by other protocadherin family members

When designing these experiments, researchers should consider the potential redundancy within the protocadherin family and the possibility that multiple family members may need to be manipulated simultaneously to observe phenotypic effects. Additionally, tissue-specific expression patterns should inform the selection of appropriate model systems, with neuronal cultures derived from brain regions known to express PCDHA2 being particularly relevant .

What are common technical issues when working with PCDHA2 antibodies and how can they be resolved?

Researchers frequently encounter several technical challenges when working with PCDHA2 antibodies. Here are the most common issues and their evidence-based solutions:

1. Multiple Bands on Western Blots:

• Issue: Detection of unexpected bands beyond the calculated 102 kDa molecular weight, particularly an 80 kDa band .

• Solution: Verify if the additional band is a known isoform or proteolytic fragment by comparing with literature reports. The 80 kDa band has been documented for PCDHA2 . Include positive control samples (brain tissue) and conduct peptide competition assays to confirm specificity.

2. Weak or Absent Signal:

• Issue: Insufficient detection despite adequate protein loading.

• Solution: Optimize protein extraction using specialized neural tissue buffers containing phosphatase inhibitors. Increase antibody concentration (starting at 1:500 dilution) , extend incubation times (overnight at 4°C), and use signal enhancement systems compatible with your detection method.

3. High Background:

• Issue: Non-specific binding obscuring specific signal.

• Solution: Implement more stringent blocking conditions (5% BSA instead of milk for phospho-proteins), increase washing duration and frequency, and decrease secondary antibody concentration. Consider using TBS-T instead of PBS-T if phospho-epitopes are involved.

4. Cross-Reactivity with Related Protocadherins:

• Issue: PCDHA2 antibodies may recognize conserved epitopes in other protocadherin family members.

• Solution: Validate specificity using tissues from knockout models if available. Alternatively, perform peptide competition assays with the immunizing peptide versus peptides from closely related family members. Pre-absorption with cross-reactive proteins can also improve specificity.

5. Variability Between Experiments:

• Issue: Inconsistent results across experimental replicates.

• Solution: Standardize sample preparation, storage conditions (-20°C with aliquoting to avoid freeze/thaw cycles) , and implement a detailed laboratory protocol with precisely defined parameters for each step. Include consistent positive controls in each experiment.

6. Epitope Masking in Fixed Tissues:

• Issue: Reduced antibody binding in fixed tissue samples.

• Solution: Optimize antigen retrieval methods, testing both heat-mediated (citrate or EDTA buffers) and enzymatic approaches (proteinase K). For some epitopes, particular fixation methods may be preferable over others (e.g., paraformaldehyde versus methanol).

When troubleshooting, systematic modification of one variable at a time while maintaining detailed records of experimental conditions will help identify optimal protocols for PCDHA2 detection in your specific experimental system.

How can researchers distinguish between specific PCDHA2 signal and potential cross-reactivity with other protocadherin family members?

Distinguishing PCDHA2-specific signals from potential cross-reactivity with other protocadherin family members presents a significant challenge due to the high sequence homology within this gene family. Implementing a multi-faceted approach is essential:

1. Epitope-Targeted Antibody Selection:

• Choose antibodies raised against unique regions of PCDHA2 rather than conserved domains

• Verify the immunogen sequence (e.g., KLH-conjugated synthetic peptide between 253-282 amino acids from the N-terminal region) for minimal overlap with other family members

• When possible, use multiple antibodies targeting different epitopes of PCDHA2

2. Molecular Validation Approaches:

• RNA Interference: Deploy siRNA or shRNA specifically targeting PCDHA2 and confirm corresponding reduction in antibody signal

• Gene Editing: Utilize CRISPR/Cas9 to generate PCDHA2-specific knockouts as definitive negative controls

• Overexpression: Express tagged PCDHA2 constructs and confirm co-localization with antibody signal

3. Comparative Expression Analysis:

• Tissue Specificity: Leverage known differential expression patterns of protocadherin family members across tissues

• Developmental Timing: Utilize the distinct temporal expression patterns of protocadherins during development

• Cell Type Profiling: Compare antibody reactivity patterns with RNA-seq or single-cell transcriptomic data

4. Biochemical Verification:

• Peptide Competition: Perform parallel assays with increasing concentrations of PCDHA2-specific peptide versus peptides from related family members

• Immunoprecipitation-Mass Spectrometry: Confirm the identity of the immunoprecipitated protein through peptide mapping

• Size Verification: Compare observed molecular weight (102 kDa, with possible 80 kDa variant) with predicted weights of other family members

5. Advanced Analytical Controls:

• Differential Expression Systems: Compare antibody reactivity in systems with verified differential expression of PCDHA2 versus other family members

• Recombinant Protein Arrays: Test antibody specificity against an array of recombinant protocadherin proteins

• Cross-Adsorption: Pre-adsorb antibodies with recombinant proteins of closely related family members before use

By implementing these approaches systematically, researchers can establish a high confidence level in the specificity of PCDHA2 detection, critical for accurate interpretation of experimental results in studies of neural development and function.

How should researchers interpret changes in PCDHA2 expression between embryonic and adult tissues in the context of neural development?

Interpreting changes in PCDHA2 expression between developmental stages requires careful consideration of its biological context within the broader protocadherin family dynamics:

Developmental Context Interpretation Framework:

• Temporal Expression Patterns:

  • Assess PCDHA2 expression relative to known developmental milestones in your model system

  • Compare with expression profiles of other protocadherin family members (particularly PCDHA4, which shows 36.1-fold higher expression in embryonic versus adult cells)

  • Consider how expression changes correlate with synaptogenesis, circuit refinement, and critical periods

• Cell Type-Specific Considerations:

  • Different neural cell populations may show distinct PCDHA2 regulation patterns

  • Evaluate whether expression changes are uniform across all neural subtypes or restricted to specific populations

  • Correlate with emergence of functional neural circuits and specific connectivity patterns

• Compensatory Mechanisms:

  • Assess whether changes in PCDHA2 are accompanied by reciprocal changes in other protocadherin family members

  • Consider the combinatorial effects of multiple protocadherin expression changes rather than focusing on PCDHA2 in isolation

  • Evaluate potential functional redundancy within the alpha cluster

• Pathological Implications:

  • Analyze how cancer cells often revert to embryonic-like protocadherin expression patterns

  • Consider how disruptions in developmental regulation of PCDHA2 might contribute to neurodevelopmental disorders

  • Evaluate whether adult re-expression of embryonic patterns occurs in injury or disease states

When quantifying expression changes, researchers should normalize data appropriately, considering both within-sample controls (housekeeping genes) and between-sample standards (reference tissues with known expression levels). Statistical analysis should account for biological variability and include sufficient biological replicates to distinguish true developmental regulation from random variation.

What advanced analytical approaches can researchers use to correlate PCDHA2 expression patterns with functional outcomes in neural circuits?

Correlating PCDHA2 expression with functional outcomes in neural circuits requires sophisticated analytical approaches that bridge molecular data with physiological and behavioral readouts:

1. Integrated Multi-omics Analysis:

• Combine transcriptomic profiling of PCDHA2 with proteomic and epigenetic data

• Implement network analysis to identify co-regulated genes and pathways

• Use weighted gene co-expression network analysis (WGCNA) to identify PCDHA2-associated functional modules

2. Single-Cell Resolution Approaches:

• Apply single-cell RNA sequencing to map PCDHA2 expression across neural subpopulations

• Correlate expression with electrophysiological properties of individual neurons

• Implement spatial transcriptomics to preserve anatomical context of expression patterns

3. Circuit Mapping Technologies:

• Use trans-synaptic tracing combined with PCDHA2 expression analysis

• Implement optogenetic or chemogenetic manipulation in PCDHA2-expressing neurons

• Apply whole-brain imaging to correlate PCDHA2 expression with functional connectivity

4. Computational Modeling Approaches:

• Develop predictive models of circuit formation based on combinatorial protocadherin expression

• Simulate the impact of PCDHA2 manipulation on network development and function

• Implement machine learning algorithms to identify complex relationships between expression patterns and functional outcomes

5. Longitudinal Developmental Analysis:

• Track PCDHA2 expression and circuit function across developmental timepoints

• Correlate changes in expression with critical periods for specific behaviors

• Implement conditional genetic manipulation to assess temporal requirements for PCDHA2

6. Comparative Cross-Species Analysis:

• Evaluate conservation of PCDHA2 expression and function across model organisms

• Correlate species-specific expression patterns with evolutionary adaptations in neural circuitry

• Implement cross-species functional rescue experiments to test conservation of mechanism

When implementing these approaches, researchers should consider several analytical principles:

• Maintain statistical rigor with appropriate sample sizes and controls

• Implement blinded analysis when assessing functional outcomes

• Consider both cell-autonomous and non-cell-autonomous effects of PCDHA2

• Account for potential redundancy and compensation within the protocadherin family

These advanced analytical strategies allow researchers to move beyond correlative observations to establish causal relationships between PCDHA2 expression and neural circuit function.

What emerging technologies and approaches show promise for advancing PCDHA2 research in neurodevelopmental disorders?

Several cutting-edge technologies and methodologies are poised to transform our understanding of PCDHA2's role in neurodevelopmental processes and disorders:

1. Advanced Genome Editing Technologies:

• Base editors and prime editors for introducing precise point mutations in PCDHA2

• CRISPR activation/interference systems for temporal and spatial control of PCDHA2 expression

• CRISPR screens targeting regulatory elements controlling PCDHA2 expression

2. Brain Organoid Models:

• Patient-derived organoids to study PCDHA2 dysfunction in neurodevelopmental disorders

• Assembloid approaches combining different brain regions to assess PCDHA2's role in circuit formation

• Long-term culture systems to model developmental trajectories and critical periods

3. Advanced Imaging Technologies:

• Super-resolution imaging to visualize PCDHA2-mediated cell-cell interactions at nanoscale resolution

• Expansion microscopy combined with multiplexed antibody labeling for comprehensive spatial mapping

• Light-sheet microscopy for whole-organ imaging of PCDHA2 expression and function

4. Synthetic Biology Approaches:

• Engineered protocadherin systems with controlled specificity to test recognition code hypotheses

• Optogenetic control of PCDHA2 interactions to manipulate cell recognition in real-time

• Synthetic circuits to probe combinatorial effects of multiple protocadherin family members

5. Multi-modal Single-Cell Technologies:

• Integrated single-cell transcriptomics, proteomics, and epigenomics

• Patch-seq approaches linking PCDHA2 expression to electrophysiological properties

• Spatial transcriptomics to preserve anatomical context of expression patterns

6. Human iPSC-Based Disease Modeling:

• Isogenic iPSC lines with PCDHA2 variants identified in neurodevelopmental disorders

• High-throughput differentiation protocols to assess PCDHA2 function across neural lineages

• Co-culture systems to evaluate cell-specific requirements for PCDHA2 in circuit formation

7. Advanced Computational Approaches:

• Deep learning algorithms for predicting functional consequences of PCDHA2 variants

• Network analysis tools integrating multi-omics data to identify PCDHA2-associated pathways

• Molecular dynamics simulations of PCDHA2 interactions based on structural data

These emerging technologies promise to address key knowledge gaps, particularly regarding how PCDHA2 contributes to the remarkable specificity of neural circuit formation and how its dysfunction may contribute to neurodevelopmental and psychiatric disorders. Researchers should consider how these approaches can be integrated into comprehensive research programs that span from molecular mechanisms to functional outcomes.

How can researchers effectively study the interplay between PCDHA2 and other protocadherin family members in combinatorial cell recognition?

Studying the combinatorial effects of PCDHA2 and other protocadherin family members requires sophisticated experimental designs that capture the complexity of their interactions:

1. Combinatorial Genetic Manipulation Strategies:

• Generate conditional knockout models targeting multiple protocadherin clusters simultaneously

• Implement inducible systems for temporal control of multiple family members

• Utilize allelic series to study dosage effects across multiple protocadherins

2. Single-Cell Multi-Omics Approaches:

• Apply single-cell RNA-seq to map the complete protocadherin repertoire of individual neurons

• Correlate expression patterns with connectivity and functional properties

• Implement computational algorithms to decode the protocadherin combinatorial code

3. Advanced Imaging of Molecular Interactions:

• Multi-color super-resolution imaging to visualize distinct protocadherin family members simultaneously

• FRET/FLIM approaches to measure direct interactions between different protocadherins

• Live-cell imaging to track dynamic changes in protocadherin interactions during development

4. Biochemical Interaction Analysis:

• Develop protein arrays containing the complete repertoire of protocadherin family members

• Implement proximity labeling approaches (BioID, APEX) to identify interaction partners in living cells

• Use structural biology approaches to determine binding interfaces between family members

5. Synthetic Biology Testing Platforms:

• Engineer cells expressing defined combinations of protocadherins to test recognition specificity

• Create chimeric protocadherins to map functional domains mediating specificity

• Develop quantitative assays measuring cell sorting and adhesion strength

6. Systems Biology Integration:

• Implement mathematical modeling of combinatorial protocadherin interactions

• Develop predictive algorithms for cell recognition based on protocadherin expression profiles

• Apply network analysis to identify emergent properties from combinatorial interactions

When designing these studies, researchers should consider several key principles:

• Biological Contextualization: Study interactions in physiologically relevant contexts where possible

• Quantitative Assessment: Develop metrics to quantify interaction strengths and specificities

• Temporal Dynamics: Consider how interactions may change during development and activity

• Functional Correlation: Link molecular interactions to functional outcomes in circuit formation

• Evolutionary Perspective: Compare combinatorial mechanisms across species to identify conserved principles

By implementing these approaches, researchers can begin to decipher the "protocadherin code" that enables the remarkable specificity of neural circuit formation through combinatorial cell surface recognition processes involving PCDHA2 and its family members.

What is the optimal protocol for immunoprecipitation of PCDHA2 from neural tissues for interaction studies?

Immunoprecipitation (IP) of PCDHA2 from neural tissues requires careful optimization to maintain protein interactions while achieving sufficient specificity and yield. This protocol incorporates evidence-based approaches for successful PCDHA2 interaction studies:

Optimized PCDHA2 Immunoprecipitation Protocol:

Materials Required:

• Fresh neural tissue (brain tissue preferred due to higher expression)

• PCDHA2 antibody validated for IP (0.5-4.0 μg per 1.0-3.0 mg of total protein lysate)

• Protein A/G magnetic beads

• Lysis and wash buffers (detailed below)

• Protease and phosphatase inhibitor cocktails

• Control IgG antibody (same species as PCDHA2 antibody)

Procedure:

• Tissue Preparation and Lysis:

  • Harvest fresh neural tissue and immediately place on ice

  • Homogenize in ice-cold lysis buffer:

    • 50 mM Tris-HCl (pH 7.4)

    • 150 mM NaCl

    • 1% NP-40 or 0.5% Triton X-100

    • 0.25% sodium deoxycholate

    • 1 mM EDTA

    • Protease inhibitor cocktail (PMSF, aprotinin, leupeptin, pepstatin A)

    • Phosphatase inhibitor cocktail

  • Use 5-10 ml of lysis buffer per gram of tissue

  • Homogenize using a Dounce homogenizer (10-15 strokes)

  • Incubate lysate on ice for 30 minutes with gentle agitation

  • Centrifuge at 14,000 × g for 15 minutes at 4°C

  • Collect supernatant and determine protein concentration

• Pre-clearing Lysate:

  • Add 50 μl of Protein A/G beads per 1 ml of lysate

  • Incubate with rotation for 1 hour at 4°C

  • Centrifuge at 1,000 × g for 5 minutes at 4°C

  • Transfer supernatant to a new tube

• Antibody Binding:

  • Divide lysate into experimental (PCDHA2 antibody) and control (IgG) samples

  • Add PCDHA2 antibody (2-4 μg per mg of protein) to experimental sample

  • Add equivalent amount of control IgG to control sample

  • Incubate with gentle rotation overnight at 4°C

• Immunoprecipitation:

  • Add 50 μl of pre-washed Protein A/G beads to each sample

  • Incubate with rotation for 4 hours at 4°C

  • Collect beads using magnetic stand

  • Wash beads 5 times with wash buffer:

    • 50 mM Tris-HCl (pH 7.4)

    • 150 mM NaCl

    • 0.1% NP-40 or Triton X-100

    • 1 mM EDTA

  • Perform final wash with PBS

• Elution and Analysis:

  • Elute proteins by adding 50 μl of 2× Laemmli sample buffer

  • Heat at 95°C for 5 minutes

  • Analyze by SDS-PAGE and Western blotting or mass spectrometry

Critical Considerations for PCDHA2 IP:

• Maintain all steps at 4°C to preserve protein-protein interactions

• Use freshly prepared tissue; avoid frozen samples if possible

• Consider crosslinking weak or transient interactions with DSP or formaldehyde

• For membrane protein complexes, evaluate detergent concentrations carefully

• Verify successful IP by Western blot using a different PCDHA2 antibody targeting a distinct epitope

This protocol has been optimized based on reported successful immunoprecipitation of PCDHA2 and general best practices for membrane protein immunoprecipitation.

How can researchers optimize Western blot protocols for detecting both the 102 kDa and 80 kDa PCDHA2 isoforms?

Detecting both the 102 kDa and 80 kDa PCDHA2 isoforms requires careful optimization of Western blot protocols to ensure accurate visualization and quantification:

Optimized Western Blot Protocol for Multiple PCDHA2 Isoforms:

Sample Preparation:

• Tissue Selection: Prioritize brain tissue where PCDHA2 expression is highest

• Extraction Buffer Composition:

  • RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)

  • Supplement with 1% Triton X-100 to enhance membrane protein extraction

  • Add protease inhibitor cocktail (PMSF, aprotinin, leupeptin, pepstatin A)

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

• Homogenization Method:

  • Use mechanical disruption (Dounce homogenizer) for tissue samples

  • Ensure complete lysis while maintaining cold temperature (4°C)

• Protein Quantification:

  • Use detergent-compatible assays (BCA or Modified Lowry)

  • Load 50-80 μg of total protein per lane

Gel Electrophoresis Optimization:

• Gel Percentage:

  • Use 8% polyacrylamide gels for optimal separation in the 80-102 kDa range

  • Consider gradient gels (4-15%) for simultaneous detection of other proteins

• Running Conditions:

  • Apply lower voltage (80-100V) for better resolution of high molecular weight proteins

  • Extend running time to ensure adequate separation

• Molecular Weight Markers:

  • Include pre-stained markers with distinct bands at 75-110 kDa range

  • Consider using a protein ladder optimized for high molecular weight proteins

Transfer Optimization:

• Transfer Method:

  • Use wet transfer for high molecular weight proteins

  • Transfer at 30V overnight at 4°C for efficient transfer of large proteins

• Membrane Selection:

  • PVDF membranes (0.45 μm pore size) for optimal binding of large proteins

  • Pre-activate PVDF with methanol prior to transfer

• Transfer Buffer:

  • Add 0.05% SDS to facilitate transfer of large proteins

  • Include 10-20% methanol to enhance binding to membrane

Immunodetection Optimization:

• Blocking Conditions:

  • 5% non-fat dry milk in TBS-T (preferred over BSA for general blocking)

  • Block for 1-2 hours at room temperature

• Primary Antibody Incubation:

  • Use 1:500 dilution as starting point (adjust based on signal strength)

  • Incubate overnight at 4°C with gentle agitation

  • Consider using antibodies targeting different epitopes for confirmation

• Washing Steps:

  • Perform 5 washes with TBS-T, 5 minutes each

  • Increase washing volume and agitation to reduce background

• Secondary Antibody:

  • Use highly cross-adsorbed secondary antibodies to minimize cross-reactivity

  • Dilute 1:5000-1:10000 in blocking buffer

  • Incubate for 1 hour at room temperature

• Detection System:

  • Use enhanced chemiluminescence with extended exposure capabilities

  • Consider gradient exposure times to capture both strong and weak bands

  • Digital imaging systems with broad dynamic range are preferred

Validation Controls:

• Positive Controls:

  • Include mouse, rat, or human brain tissue as positive controls

  • Consider using Raji cells or HeLa cells which have documented PCDHA2 expression

• Band Verification:

  • Perform peptide competition assays to confirm specificity of both bands

  • Consider IP-Western to enrich for PCDHA2 prior to detection

This optimized protocol addresses the specific challenges of detecting multiple PCDHA2 isoforms and is based on documented successful detection of both the 102 kDa and 80 kDa forms .

What are the most reliable resources for PCDHA2 sequence information, expression data, and validated reagents?

Researchers seeking comprehensive and reliable information about PCDHA2 should consult these authoritative resources:

1. Sequence and Structural Resources:

2. Expression and Functional Resources:

3. Validated Reagents and Tools:

4. Literature Resources:

5. Disease and Clinical Resources: